<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21070" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatic Encephalopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mandiga</surname>
            <given-names>Pujyitha</given-names>
          </name>
          <aff>Genesys Regional Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kommu</surname>
            <given-names>Sharath</given-names>
          </name>
          <aff>Marshfield Clinic Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bollu</surname>
            <given-names>Pradeep C.</given-names>
          </name>
          <aff>University of Missouri</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pujyitha Mandiga declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sharath Kommu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradeep Bollu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21070.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hepatic encephalopathy is a serious and potentially reversible condition that can affect individuals with advanced liver dysfunction. It is characterized by a range of neuropsychiatric and neuromuscular abnormalities resulting from the buildup of toxic substances in the bloodstream, ultimately impacting brain function. While commonly associated with underlying liver conditions such as cirrhosis, it can also develop in individuals without prior hepatic issues who develop acute liver failure. While hepatic encephalopathy in chronic liver failure like cirrhosis may be reversible, when secondary to acute liver failure, it can lead to brain edema and prove challenging to manage.&#x000a0;Patients can also develop this condition in the setting of portosystemic shunts.&#x000a0;</p>
        <p>This activity discusses the etiology, epidemiology, pathophysiology, evaluation, and treatment approaches for hepatic encephalopathy.&#x000a0;The course&#x000a0;covers the disease staging, potential complications, prognosis, and patient education regarding this condition. Additionally, emphasis is placed on the vital contributions of an interprofessional healthcare team in both the prevention and management of this condition, aiming to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms of hepatic encephalopathy, including altered mental status, confusion, and neuromuscular dysfunction, in patients with advanced liver dysfunction.</p></list-item><list-item><p>Apply routine assessments for hepatic encephalopathy using standardized tools, especially in patients with chronic liver disease or acute liver failure.</p></list-item><list-item><p>Apply evidence-based interventions, including pharmacotherapy, dietary modifications, and management of precipitating factors, to treat hepatic encephalopathy.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members, including hepatologists, neurologists, and dietitians, to provide comprehensive care and optimize patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21070&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21070">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21070.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hepatic encephalopathy is a potentially reversible syndrome that can occur in individuals with advanced liver dysfunction.&#x000a0;It is characterized by a range of neuropsychiatric abnormalities caused by the accumulation of neurotoxic substances in the bloodstream. While it is often associated with preexisting liver conditions like cirrhosis, it can also develop in individuals without prior hepatic issues. In cases without preexisting liver disease, acute severe liver failure can lead to brain swelling and, in severe cases, coma.<xref ref-type="bibr" rid="article-21070.r1">[1]</xref> Hepatic encephalopathy in patients with chronic liver disease can potentially be reversed and managed. However, when it occurs acutely with rapidly increasing blood ammonia levels (fulminant), it becomes more challenging to control due to widespread brain swelling and structural brainstem injuries.<xref ref-type="bibr" rid="article-21070.r1">[1]</xref></p>
        <p>Hepatic encephalopathy symptoms can result from liver insufficiency or the redirection of blood flow away from the liver (portosystemic shunting). According to the consensus of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism, the onset of overt hepatic encephalopathy is defined as the appearance of disorientation or asterixis.<xref ref-type="bibr" rid="article-21070.r2">[2]</xref> Identifying the onset in patients with advanced liver disease can be challenging. Some patients may exhibit subtle signs that can only be detected through specialized tests, a condition referred to as minimal hepatic encephalopathy&#x02014;observed in as many as 80% of patients with cirrhosis.<xref ref-type="bibr" rid="article-21070.r3">[3]</xref><xref ref-type="bibr" rid="article-21070.r4">[4]</xref><xref ref-type="bibr" rid="article-21070.r5">[5]</xref></p>
        <p>Symptoms of hepatic encephalopathy include confusion, personality alterations, disorientation, and reduced consciousness. In the initial stages, a disrupted sleep-wake pattern is often present, where patients tend to sleep during the day and stay awake at night. As the condition progresses through intermediate stages, patients typically encounter increasing levels of confusion, lethargy, and personality shifts. In advanced stages, hepatic encephalopathy can eventually lead to coma, known as hepatic coma or coma hepaticum, which can be fatal. In cases of severe encephalopathy among patients with acute liver failure or known cirrhosis, the mortality rate exceeds 50% within the first year.<xref ref-type="bibr" rid="article-21070.r6">[6]</xref><xref ref-type="bibr" rid="article-21070.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21070.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hepatic encephalopathy can develop as a result of&#x000a0;underlying liver disease (synthetic encephalopathy) or related to portosystemic shunts (such as transjugular intrahepatic portosystemic shunt [TIPS] or spontaneous shunts). The former is related to liver disease, while the latter is related to portal circulation being shunted to the systemic circulation, bypassing the liver and resulting in the accumulation of toxic metabolites.<xref ref-type="bibr" rid="article-21070.r8">[8]</xref></p>
        <p>Acute liver failure can be triggered by viral hepatitis, exposure to hepatotoxins (such as acetaminophen, mushrooms, and alcohol), and ischemic liver injury (eg, septic shock). Chronic liver failure with cirrhosis may stem from causes such as alcoholic cirrhosis, chronic viral hepatitis B or C, nonalcoholic fatty liver disease (NAFLD), hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency.</p>
        <p>In the context of cirrhosis of the liver, hepatic encephalopathy can be triggered by various factors, such as the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>renal failure</p>
          </list-item>
          <list-item>
            <p>gastrointestinal bleeding (such as from esophageal varices)</p>
          </list-item>
          <list-item>
            <p>constipation</p>
          </list-item>
          <list-item>
            <p>infections</p>
          </list-item>
          <list-item>
            <p>medication noncompliance</p>
          </list-item>
          <list-item>
            <p>excessive dietary protein intake</p>
          </list-item>
          <list-item>
            <p>dehydration (due to factors like fluid restriction, diuretics, diarrhea, vomiting, or excessive paracentesis)</p>
          </list-item>
          <list-item>
            <p>electrolyte imbalances</p>
          </list-item>
          <list-item>
            <p>alcohol consumption</p>
          </list-item>
          <list-item>
            <p>the use of specific sedatives or medications (like analgesics)</p>
          </list-item>
        </list>
        <p>Furthermore, hepatic encephalopathy can be a complication in 30% to 50% of cirrhosis patients who undergo TIPS.<xref ref-type="bibr" rid="article-21070.r8">[8]</xref><xref ref-type="bibr" rid="article-21070.r9">[9]</xref><xref ref-type="bibr" rid="article-21070.r10">[10]</xref>&#x000a0;Spontaneous portosystemic shunts, occurring when fetal shunt pathways between the portal and systemic circulation open due to cirrhosis, may also be an important contributor to hepatic encephalopathy. Eventually, the systemic shunt increases in volume, portal circulation declines, and liver failure is exacerbated.<xref ref-type="bibr" rid="article-21070.r11">[11]</xref></p>
      </sec>
      <sec id="article-21070.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>One population-based study estimated that within a 5-year period, approximately 44% of individuals with cirrhosis may develop hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r12">[12]</xref>&#x000a0;In another study of over 9000 newly diagnosed cirrhosis patients, it was found that around one-third had decompensated cirrhosis, and of these, 51% experienced hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r13">[13]</xref></p>
        <p>Chronic liver disease often has a subtle and gradual onset, causing many patients to delay seeking treatment until complications emerge. A study based on the commercial medical claims database reported that the prevalence of hepatic encephalopathy in the United States in 2018 was estimated at 202,000 cases.<xref ref-type="bibr" rid="article-21070.r14">[14]</xref> However, it is important to note that this study may not have included cases of minimal hepatic encephalopathy, which can affect up to 80% of patients with cirrhosis and is characterized by subtle features that require specialized testing for detection.<xref ref-type="bibr" rid="article-21070.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21070.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The neuropathology of hepatic encephalopathy was initially described in 1949, yet our understanding of its exact causes and mechanisms remains incomplete.<xref ref-type="bibr" rid="article-21070.r1">[1]</xref> One central aspect of the pathogenesis of hepatic encephalopathy is the role of elevated serum ammonia levels. Colonic bacteria and mucosal enzymes break down dietary proteins, releasing ammonia within the gastrointestinal tract. This ammonia then enters the liver's portal circulation, where it is normally converted into urea through the urea cycle. However, in cases of hepatic failure or systemic shunt, ammonia can accumulate and be diverted into the systemic circulation. This buildup of ammonia, known as hyperammonemia, disrupts neuronal function, ultimately contributing to encephalopathy. Ammonia is one of several neurotoxic substances that can impair excitatory neurotransmission.<xref ref-type="bibr" rid="article-21070.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold>Individuals with Chronic Liver Failure/Cirrhosis</bold>
</p>
        <p>In patients with long-standing cirrhosis, another potential factor contributing to hepatic encephalopathy is manganese toxicity. This can be observed through magnetic resonance imaging (MRI), particularly in T1-weighted imaging, where abnormalities in the globus pallidus may become apparent.<xref ref-type="bibr" rid="article-21070.r16">[16]</xref> Additionally, several other substances and factors have been implicated in the development of hepatic encephalopathy, including mercaptans, short fatty acids, reduced glutaminergic synaptic function, lactate, and dopamine metabolites.<xref ref-type="bibr" rid="article-21070.r17">[17]</xref></p>
        <p>
<bold>Individuals with Acute Liver Failure without Preexisting Liver Disease</bold></p>
        <p>In individuals without preexisting liver disease, acute fulminant hepatic failure can lead to the accumulation of ammonia. Ammonia can cross the blood-brain barrier and enter the brain, where astrocytic glutamine synthetase converts it and glutamate into glutamine.<xref ref-type="bibr" rid="article-21070.r18">[18]</xref> Glutamine acts as an osmolyte, causing an increase in cerebral volume. This, in turn, results in brain edema, intracranial hypertension, and the potential risk of brain herniation.<xref ref-type="bibr" rid="article-21070.r18">[18]</xref></p>
        <p>Serum ammonia levels directly affect the severity of hepatic encephalopathy in cirrhosis patients. However, this correlation is not linear or exponential. It appears to be more pronounced in patients experiencing fulminant hepatic failure. In such cases, the risk of cerebral edema escalates when arterial ammonia levels surpass 200 &#x003bc;mol/L (equivalent to 340 &#x003bc;g/dL).<xref ref-type="bibr" rid="article-21070.r1">[1]</xref></p>
      </sec>
      <sec id="article-21070.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In cases of cirrhosis, notable morphological alterations primarily affect astrocytes and microglia within the brain.<xref ref-type="bibr" rid="article-21070.r19">[19]</xref>&#x000a0;These changes in astrocytes are often referred to as "Alzheimer type II astrocytosis" and are consistently observed in brain tissue sections of those who succumbed to grade 4 hepatic encephalopathy. Under microscopic examination, hyperammonemia may lead to the enlargement of astrocytes, which appear pale due to decreased chromatin content. It is important to note that these changes typically occur after prolonged exposure to hyperammonemia and are not commonly associated with fulminant hepatic failure. Given that the most prominent neuropathological changes seen in individuals with cirrhosis and hepatic encephalopathy involve glial cells rather than neurons, this condition has been described as a "primary gliopathy."<xref ref-type="bibr" rid="article-21070.r19">[19]</xref></p>
      </sec>
      <sec id="article-21070.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>To diagnose hepatic encephalopathy, liver disease should be confirmed through abnormal liver function tests, radiologic imaging, or liver biopsy. Alternatively, the presence of a portosystemic shunt may be diagnosed. Additionally, it is crucial to rule out other potential causes or etiologies that can mimic this condition, including intracranial lesions, masses, stroke, seizure activity, post-seizure encephalopathy, intracranial infections, or toxic encephalopathy from other known causes.</p>
        <p>
<bold>History</bold>
</p>
        <p>Obtaining the patient's medical history is invaluable in providing insights into the likely causes of liver failure and guiding appropriate interventions. In cases where the patient cannot communicate, it is essential to interview close family members, caretakers, and friends who can provide relevant information.</p>
        <p>When gathering a patient's medical history, it is important to inquire about the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms related to liver failure and its complications, such as jaundice, pruritus, gastrointestinal bleeding, coagulopathy, increased abdominal girth, renal failure, and changes in mental status&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alterations in sleep patterns and cognitive capacity may manifest as decreased attention span and impaired short-term memory, potentially leading to difficulties in daily activities.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>History of exposure to hepatotoxins, including alcohol use, medication use, and herbal medicines. Other potential hepatotoxins include mushrooms, organic solvents, or phosphorus-containing substances, such as those found in fireworks.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Risk factors for viral hepatitis, including travel, blood transfusions, sexual contacts, or occupation&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Family history of liver disease, including conditions like Wilson disease or alpha-1 antitrypsin deficiency&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A precipitating cause for encephalopathy, such as constipation, infection, use of sedatives, episodes of gastrointestinal bleeding, or conditions leading to hypovolemia, such as diarrhea or vomiting</p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>
<bold>Signs of chronic liver failure</bold>
</p>
        <p>During a physical examination, patients with hepatic encephalopathy typically exhibit signs of advanced chronic liver disease, often referred to as decompensated cirrhosis. These physical findings may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>muscle wasting</p>
          </list-item>
          <list-item>
            <p>jaundice</p>
          </list-item>
          <list-item>
            <p>ascites (fluid accumulation in the abdomen)</p>
          </list-item>
          <list-item>
            <p>palmar erythema (reddening of the palms)</p>
          </list-item>
          <list-item>
            <p>edema (swelling)</p>
          </list-item>
          <list-item>
            <p>spider telangiectasias (small, dilated blood vessels near the skin's surface)</p>
          </list-item>
          <list-item>
            <p>a distinctive odor known as fetor hepaticus</p>
          </list-item>
        </list>
        <p>However, in patients with acute fulminant hepatitis without a history of chronic liver disease, some of these findings, such as muscle wasting, spider telangiectasias, and palmar erythema, are typically absent. These physical signs require a more extended period of hepatic dysfunction for development. It is worth noting that decreased muscle mass, strength, and function, a condition known as sarcopenia, is often observed in patients with cirrhosis and is associated with an increased risk of hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r20">[20]</xref><xref ref-type="bibr" rid="article-21070.r21">[21]</xref></p>
        <p>
<bold>Neurocognitive and neuromuscular signs</bold>
</p>
        <p>Hepatic encephalopathy is characterized by changes in neurocognitive function and impaired neuromuscular performance. The neurocognitive manifestations are variable.<xref ref-type="bibr" rid="article-21070.r22">[22]</xref> Typically, the initial signs involve a reduced awareness of one's surroundings and stimuli, accompanied by behaviors such as yawning and episodes of dozing off. Disturbances in the diurnal sleep pattern, which can manifest as insomnia or hypersomnia, are common and often precede other mental status changes or neuromuscular symptoms.</p>
        <p>Neuromuscular manifestations of hepatic encephalopathy include various signs, including bradykinesia (slowness of movement), asterixis (flapping motions of outstretched, dorsiflexed hands), slurred speech, ataxia (lack of coordination), hyperactive deep tendon reflexes, and nystagmus. Asterixis is typically observed during the intermediate stages of hepatic encephalopathy.</p>
        <p>As hepatic encephalopathy progresses, patients may experience jactitations (restless tossing and muscle or limb twitching), which can merge with multifocal myoclonus. Additional physical signs may include hyperreflexia, a positive Babinski sign, or symptoms resembling Parkinsonian features such as rigidity or tremors. Less frequently, patients may develop loss of reflexes, transient decerebrate posturing, and even progression to a comatose state. Some individuals may present with focal neurological deficits despite negative findings on CT or MRI of the brain.<xref ref-type="bibr" rid="article-21070.r23">[23]</xref></p>
      </sec>
      <sec id="article-21070.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing hepatic encephalopathy should begin with a comprehensive assessment of the patient's vital signs and airway. Additionally, it is crucial to make a careful distinction between the presence of asterixis and tremulousness, as these manifestations can sometimes be associated with alcohol withdrawal or abuse. Various tests include the following:&#x000a0;</p>
        <p><bold>Ammonia levels&#x000a0;</bold>are generally elevated&#x000a0;in both arterial and venous blood. While ammonia is a known neurotoxin, elevated levels are&#x000a0;not a requirement for hepatic encephalopathy. In clinical practice, assessing a patient's clinical improvement or deterioration during treatment is more valuable than relying solely on serial measurements of blood ammonia. Neither elevated arterial nor venous ammonia concentrations are sufficient for diagnosing hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r24">[24]</xref></p>
        <p><bold>Hepatic function tests and electrolytes</bold> are commonly abnormal&#x000a0;due to underlying liver disease. This may manifest as elevated levels of bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, prothrombin time, and International Normalized Ratio (INR). Additionally, patients may experience electrolyte imbalances such as hyponatremia and hypokalemia due to hepatic dysfunction or the use of diuretics.</p>
        <p><bold>Serum 3-nitrotyrosine level</bold> elevation&#x000a0;may be observed in patients with mild hepatic encephalopathy. Research has indicated that using a cutoff of 14 nM, 3-nitrotyrosine can demonstrate a sensitivity of 93% and specificity of 89% for detecting minimal hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r25">[25]</xref></p>
        <p><bold>Psychometric tests</bold>&#x000a0;have been developed and assessed to measure the extent of mental function impairment in individuals with mild stages of hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r3">[3]</xref><xref ref-type="bibr" rid="article-21070.r26">[26]</xref><xref ref-type="bibr" rid="article-21070.r27">[27]</xref><xref ref-type="bibr" rid="article-21070.r28">[28]</xref><xref ref-type="bibr" rid="article-21070.r29">[29]</xref> These tests have shown greater sensitivity than electroencephalogram (EEG) in identifying minor mental function deficits.<xref ref-type="bibr" rid="article-21070.r26">[26]</xref> However, it's worth noting that many of these tests are complex, time-consuming, and not commonly employed as standard clinical tools.</p>
        <p>The number connection test (NCT), also known as the Reitan Test, is one of the most commonly utilized psychometric tests.<xref ref-type="bibr" rid="article-21070.r27">[27]</xref><xref ref-type="bibr" rid="article-21070.r28">[28]</xref><xref ref-type="bibr" rid="article-21070.r30">[30]</xref> It offers the advantage of being easy to administer and interpret. The NCT involves a timed task of connecting numbers in sequence. Patients without hepatic encephalopathy typically complete the test in a number of seconds &#x02264; their age in years. For instance, if a patient is aged 50,&#x000a0;she&#x000a0;should be able to finish the test in 50 seconds or less.</p>
        <p><bold>Electroencephalogram&#x000a0;</bold>activity captures changes like high-amplitude low-frequency waves and triphasic waves, which can be observed in hepatic encephalopathy. However, these findings are not specific to the syndrome. An EEG can be valuable during the initial evaluation to rule out seizure activity.</p>
        <p><bold>Radiologic imaging</bold>, such as CT or MRI, may be utilized to rule out alternative causes of encephalopathy, including the presence of intracranial lesions, masses, or hemorrhage. In some cases, a CT scan in hepatic encephalopathy may reveal generalized or localized cerebral edema. While MRI is considered superior to CT for diagnosing brain edema in liver failure, it is not an established method for diagnosing hepatic encephalopathy. In certain instances, changes have been observed on T1-weighted MRI images, showing a strong signal in the basal ganglia in patients with hepatic encephalopathy, possibly due to manganese accumulation.<xref ref-type="bibr" rid="article-21070.r31">[31]</xref> However, it is important to note that these changes are neither highly sensitive nor specific indicators.<xref ref-type="bibr" rid="article-21070.r32">[32]</xref><xref ref-type="bibr" rid="article-21070.r33">[33]</xref></p>
      </sec>
      <sec id="article-21070.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p> The management of hepatic encephalopathy typically includes supportive care and ammonia-lowering therapy. Supportive care is a crucial aspect of management, and it encompasses several key elements, including supporting nutrition, avoiding dehydration and electrolyte abnormalities, and providing a safe environment to prevent accidents or falls. Disaccharides such as lactulose and lactitol and antibiotics like rifaximin are the key components of ammonia-lowering therapy.</p>
        <p><bold>Nutritional support:</bold> Patients with hepatic encephalopathy should not have protein intake restricted. Instead, they should receive nutritional support that provides an appropriate energy intake of approximately 35 to 40 kcal/kg/day. This dietary plan should maintain protein intake at around 1.2 to 1.5 gm/kg/day. It's important to emphasize the consumption of small meals throughout the day to prevent fasting, which can lead to increased ammonia production. For patients who experience worsening symptoms with protein intake, exploring vegetable protein as an alternative may be considered. Additionally, for individuals intolerant to protein, adding branched-chain amino acids (BCAA) to a low-protein diet can be explored. This approach is particularly beneficial for patients undergoing procedures like TIPS or surgical portosystemic shunts and experiencing hepatic encephalopathy.</p>
        <p><bold>Hydration and electrolyte correction:</bold> Supportive care also includes ensuring proper hydration and correcting electrolyte imbalances. This involves providing adequate oral fluids and, when necessary, administering intravenous hydration to prevent dehydration. Additionally, any electrolyte abnormalities should be addressed by appropriately replacing essential electrolytes.</p>
        <p><bold>Safe environment:</bold>&#x000a0;Establishing a safe environment for patients with overt symptoms is essential. These individuals may exhibit agitation and pose a risk to both themselves and their caregivers. While addressing the patient's agitation, it is crucial to note that sedative medications, such as benzodiazepines, can potentially exacerbate encephalopathy and impede recovery. Therefore, their use should be approached judiciously, and in some cases, temporary restraint measures may be necessary until the patient's agitation subsides.</p>
        <p><bold>Addressing and treating the precipitating factors:</bold>&#x000a0;It is paramount to identify and address the precipitating causes of hepatic encephalopathy promptly. These triggers may encompass various factors such as constipation, infections (including spontaneous bacterial peritonitis or urinary tract infections), electrolyte and metabolic abnormalities (eg, hypokalemia or hypoglycemia), hypovolemia, and the use of benzodiazepines or other sedatives. Timely intervention to correct these precipitating factors is essential for effective management.</p>
        <p><bold>Lowering ammonia:</bold> In most hepatic encephalopathy cases, ammonia levels are elevated; however, they may not be elevated in every instance. Regardless of whether ammonia levels are elevated, once the diagnosis of hepatic encephalopathy is established, steps should be taken to reduce the ammonia levels. Conversely, when serum ammonia levels are elevated without concurrent clinical signs of hepatic encephalopathy, it is essential to understand that this alone does not warrant ammonia-lowering therapy. The decision to initiate such therapy should be based on clinical assessment and the presence of hepatic encephalopathy symptoms rather than ammonia levels alone. Commonly used medications for management include disaccharides like lactulose and lactitol, as well as the antibiotic rifaximin.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lactulose</bold>: Lactulose operates through multiple mechanisms of action. When bacterial degradation of lactulose occurs in the gut, it leads to an acidic pH environment. This, in turn, facilitates the conversion of ammonia (NH3) to ammonium (NH4+), reducing the diffusion of NH3 into the bloodstream. Additionally, lactulose enhances NH3 diffusion from the blood into the gut, where conversion to NH4+ occurs. Furthermore, it exerts an osmotic effect in the colon, promoting distention and peristalsis, which aids in the excretion of NH3. Through these mechanisms, lactulose effectively reduces blood ammonia concentration. Typically, it is administered at a dose of 20 to 30 grams, 2 to&#x000a0;4 times per day, to achieve at least&#x000a0;2 to&#x000a0;3 soft stools daily. In cases where oral administration is not feasible, it can also be given as an enema. Approximately 70% to 80% of patients with hepatic encephalopathy show improvement with lactulose treatment.<xref ref-type="bibr" rid="article-21070.r34">[34]</xref><xref ref-type="bibr" rid="article-21070.r35">[35]</xref><xref ref-type="bibr" rid="article-21070.r36">[36]</xref> While lactitol is available in various countries, it is not available in the United States.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Rifaximin</bold>: Rifaximin is an antibiotic that is poorly absorbed in the gastrointestinal tract, thereby creating a higher intestinal concentration. It is believed to reduce ammonia production by targeting and eliminating ammonia-producing bacteria in the colon. Rifaximin achieves this by binding to bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis. It can be considered for patients who do not respond to lactulose or lactitol or for those who experience intolerance to these medications. Rifaximin is typically prescribed at a dose of 550 mg orally twice daily or 400 mg orally&#x000a0;3 times daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neomycin</bold>: Another antibiotic, neomycin, was previously explored to reduce ammonia-producing colonic bacteria. However, evidence from randomized trials on neomycin has shown inconsistent results in managing hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r37">[37]</xref><xref ref-type="bibr" rid="article-21070.r38">[38]</xref> Additionally, neomycin risks adverse effects, including potential ototoxicity and nephrotoxicity. As a result, neomycin is not routinely used due to limited efficacy and associated risks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ornithine-aspartate</bold>: Ornithine-aspartate, a compound that stimulates the metabolism of ammonia and enhances its utilization in the urea cycle to produce urea, serves as an alternative treatment for hepatic encephalopathy. However, this is&#x000a0;not always clinically available.<xref ref-type="bibr" rid="article-21070.r39">[39]</xref></p>
          </list-item>
        </list>
        <p><bold>Chronic management:</bold> For individuals at risk of recurrent hepatic encephalopathy, it is crucial to identify and manage any potential precipitating factors. If a precipitating factor cannot be identified or effectively controlled, patients can benefit from ongoing therapy with disaccharides like lactulose or lactitol in combination with rifaximin.</p>
        <p><bold>Liver transplantation:</bold> In a patient with cirrhosis, liver transplantation is typically considered when there is a major-index complication (such as ascites, hepatic encephalopathy, or variceal bleeding) or when the Model of End-Stage Liver Disease (MELD) score exceeds 15.<xref ref-type="bibr" rid="article-21070.r40">[40]</xref>&#x000a0;In patients who are candidates for and undergo liver transplantation, cognitive impairment associated with hepatic encephalopathy appears to be reversible within 5 years following the transplantation procedure.<xref ref-type="bibr" rid="article-21070.r41">[41]</xref> This underscores the potential for significant improvement in cognitive function and quality of life after successful liver transplantation.</p>
      </sec>
      <sec id="article-21070.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of hepatic encephalopathy includes the categories as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intracranial lesions: subdural hematoma, intracranial hemorrhage, tumor, stroke, abscess&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Other primary central nervous system processes: meningitis,&#x000a0;Wernicke encephalopathy, post-seizure&#x000a0;encephalopathy</p>
          </list-item>
          <list-item>
            <p>Metabolic causes: hypoglycemia, anoxia, alcohol intoxication, alcohol withdrawal&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;<bold> &#x000a0; &#x000a0;&#x000a0;</bold></p>
          </list-item>
          <list-item>
            <p>Drug-related effects: antipsychotics, sedatives, antidepressants</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21070.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Several other treatment strategies have been explored, some showing promising results in managing hepatic encephalopathy.</p>
        <p><bold>BCAA infusions</bold><bold>:</bold> Various randomized trials have examined the use of parenteral nutrition with modified amino acid solutions containing a high content of branched-chain amino acids (BCAA) and a low content of aromatic amino acids (AAA), as patients with cirrhosis tend to be more depleted of BCAA compared to AAA. However, there is conflicting evidence on mortality effects, and study numbers have so far been very small with short follow-ups. Consequently, BCAA infusions are not routinely recommended for hepatic encephalopathy management.<xref ref-type="bibr" rid="article-21070.r42">[42]</xref></p>
        <p><bold>Oral BCAA supplements:</bold>&#x000a0;Several trials have studied the effects of oral BCAA supplements with beneficial effects on hepatic encephalopathy, although no observable mortality benefits. Patients with hyperammonemia are prone to depletion of amino acids in general, and branched-chain amino acids, in particular, are building blocks for neurotransmitter and muscle generation, which is why this may be effective.<xref ref-type="bibr" rid="article-21070.r39">[39]</xref><xref ref-type="bibr" rid="article-21070.r43">[43]</xref><xref ref-type="bibr" rid="article-21070.r44">[44]</xref></p>
        <p><bold>Polyethylene glycol:</bold> Polyethylene glycol (PEG) solution, a cathartic, can enhance ammonia excretion in the stool. Many studies find that patients who were administered PEG experienced more substantial improvements in their hepatic encephalopathy scoring algorithm (HESA) scores than those who received lactulose. Consequently, these results support the consideration of PEG as a viable option for treating hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r45">[45]</xref><xref ref-type="bibr" rid="article-21070.r46">[46]</xref></p>
        <p><bold>Sodium benzoate:</bold> Sodium benzoate operates by reducing ammonia levels through a chemical reaction with glycine, forming hippurate, which is subsequently excreted via the kidneys.&#x000a0;One trial showed sodium benzoate&#x000a0;yielded similar improvements in encephalopathy as lactulose.<xref ref-type="bibr" rid="article-21070.r47">[47]</xref> While these results are promising, additional research is necessary to determine the position of this medication as a first- or second-line therapy.</p>
        <p><bold>Probiotics:</bold> Probiotic therapy has demonstrated the potential to reduce blood ammonia concentrations, potentially by promoting the colonization of acid-resistant, non-urease-producing bacteria, with Lactobacilli and Bifidobacteria being the most effective species for hepatic encephalopathy management. Probiotics are often used empirically because of the perceived benign nature of the intervention, but rigorous, supportive data is lacking.<xref ref-type="bibr" rid="article-21070.r22">[22]</xref><xref ref-type="bibr" rid="article-21070.r48">[48]</xref></p>
        <p><bold>Flumazenil:</bold> Flumazenil, a benzodiazepine receptor antagonist, may offer temporary improvement in patients with hepatic encephalopathy. However,&#x000a0;a&#x000a0;large meta-analysis found that flumazenil did not impact all-cause mortality.&#x000a0;There is some evidence of short-term benefit, but it is not a recommended treatment for patients with hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r49">[49]</xref>&#x000a0;</p>
        <p><bold>Zinc:</bold> Zinc deficiency is prevalent in patients with cirrhosis and hepatic encephalopathy.<xref ref-type="bibr" rid="article-21070.r50">[50]</xref> Studies investigating zinc supplementation have yielded inconsistent results. Consequently, routine recommendations for zinc supplementation in this context are not established.</p>
        <p>Other agents being explored include L-carnitine, serotonin antagonists, and opioid antagonists, among others. Further investigation is necessary to comprehensively assess their effectiveness.</p>
      </sec>
      <sec id="article-21070.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Hepatic encephalopathy may be classified according to the West Haven Criteria (a semi-quantitative grading of mental state based on the level of dependence on therapy and the impairment&#x000a0;in autonomy, behavior, consciousness, and intellectual function)&#x000a0;or the World Health Congress of Gastroenterology Criteria (based on the underlying etiology and associated conditions).<xref ref-type="bibr" rid="article-21070.r51">[51]</xref></p>
        <p>
<bold>West Haven Criteria</bold>
<bold/>
</p>
        <p>Grade 1</p>
        <list list-type="bullet">
          <list-item>
            <p>Trivial lack of awareness</p>
          </list-item>
          <list-item>
            <p>Euphoria or anxiety</p>
          </list-item>
          <list-item>
            <p>Shortened attention span, impaired performance of addition or subtraction</p>
          </list-item>
        </list>
        <p>Grade 2</p>
        <list list-type="bullet">
          <list-item>
            <p>Lethargy or apathy</p>
          </list-item>
          <list-item>
            <p>Minimal disorientation for time or place</p>
          </list-item>
          <list-item>
            <p>Subtle personality change</p>
          </list-item>
          <list-item>
            <p>Inappropriate behavior</p>
          </list-item>
        </list>
        <p>Grade 3</p>
        <list list-type="bullet">
          <list-item>
            <p>Somnolence to semi-stupor but responsive to verbal stimuli</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Gross disorientation</p>
          </list-item>
        </list>
        <p>Grade 4</p>
        <list list-type="bullet">
          <list-item>
            <p>Coma</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>World Health Congress of Gastroenterology Criteria</bold></p>
        <p>Type A (acute): Hepatic encephalopathy associated with acute liver failure, typically with cerebral edema</p>
        <p>Type B (bypass): Hepatic encephalopathy caused by portal-systemic shunting (without associated intrinsic liver disease)</p>
        <p>Type C (cirrhosis): Hepatic encephalopathy in patients with cirrhosis is subdivided into episodic, persistent, and minimal encephalopathy.</p>
        <p>
<bold>Minimal Hepatic Encephalopathy&#x000a0;</bold>
</p>
        <p>As noted above, this form is not associated with any grossly&#x000a0;evident signs of cognitive dysfunction but with cognitive deficits that can be demonstrated with neuropsychological testing.<xref ref-type="bibr" rid="article-21070.r5">[5]</xref>&#x000a0;This form has been shown to impair overall quality of life and ability to work and has been associated with a higher risk of motor vehicle&#x000a0;accidents. Psychometric testing remains the standard for diagnosis of minimal hepatic encephalopathy, including the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and PSE-Syndrome-Test which both incorporate a number of neuropsychological tests aimed at measuring multiple domains of cognitive function (which tend to be more reliable than tests of single domains of cognitive function). Treatment with rifaximin or lactulose has also&#x000a0;been shown to improve the&#x000a0;quality of life in patients with minimal hepatic encephalopathy. Rifaximin has furthermore been shown to improve driving performance in simulated experiments. The combination of both rifaximin and lactulose has been shown to prevent the recurrence of episodic hepatic encephalopathy.</p>
        <p>
<bold>General Classification</bold>
</p>
        <p>Hepatic encephalopathy is often categorized broadly into&#x000a0;2 main categories: overt or covert. Exact statistics do not exist about the relative forms of either, and these categories represent a spectrum. The covert form consists of minimal hepatic encephalopathy and West Haven grade 1. Overt hepatic encephalopathy encompasses the other categories.<xref ref-type="bibr" rid="article-21070.r52">[52]</xref></p>
      </sec>
      <sec id="article-21070.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with chronic liver disease who experience hepatic encephalopathy are at risk of recurrence. Even after treatment, individuals may continue to have persistent neurological deficits despite their mental status seemingly returning to normal. The severity of residual impairment tends to be higher in those who have experienced multiple overt episodes. Additionally, hepatic encephalopathy carries poor prognostic significance for those with liver failure.<xref ref-type="bibr" rid="article-21070.r53">[53]</xref>&#x000a0;Another study involving hospitalized patients with hepatic encephalopathy showed a 44% probability of survival at 12 months and a 35% probability at 24 months.<xref ref-type="bibr" rid="article-21070.r54">[54]</xref></p>
      </sec>
      <sec id="article-21070.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with hepatic encephalopathy include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Agitation posing a potential risk of harm to both themselves and their caregivers&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Seizures&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Residual cognitive impairment even in&#x000a0;patients who demonstrate clinical improvement.</p>
          </list-item>
          <list-item>
            <p>Decreased likelihood of survival within 12 to 24 months for patients with recurrent episodes</p>
          </list-item>
          <list-item>
            <p>Cerebral edema, seizures, and brain herniation in patients with acute&#x000a0;fulminant hepatic failure</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21070.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>One study of patients with cirrhosis who underwent non-hepatic surgery revealed that 7.2% developed hepatic encephalopathy postoperatively.<xref ref-type="bibr" rid="article-21070.r55">[55]</xref> The development of postoperative hepatic encephalopathy can be linked to adverse outcomes. Therefore, it is crucial to improve a patient's preoperative Child-Turcotte-Pugh (CTP) score and address hemodynamic and metabolic abnormalities before considering elective surgery to reduce the risk of postoperative hepatic encephalopathy.&#x000a0;Additionally, selecting anesthetics with lower hepatotoxicity may contribute to better outcomes.<xref ref-type="bibr" rid="article-21070.r55">[55]</xref><xref ref-type="bibr" rid="article-21070.r56">[56]</xref></p>
        <p>In the postoperative period and during the rehabilitation phase after surgery, it is essential to closely monitor abnormalities in electrolyte abnormalities, avoid constipation, and prevent infections. Particular attention should be given to nutritional supplementation. Ensuring adequate caloric intake is crucial, and protein restriction should be avoided. It is important to steer clear of medications that can be nephrotoxic or hepatotoxic, and sedatives should be used with extreme caution.<xref ref-type="bibr" rid="article-21070.r57">[57]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21070.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations with specialists may be indicated for management.&#x000a0;These specialists include gastroenterologists, hepatologists, neurologists, neurointensivists, interventional radiologists for TIPS, and transplant surgeons.</p>
      </sec>
      <sec id="article-21070.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients at risk for hepatic encephalopathy should receive education about the condition, covering various aspects such as symptoms, triggers, chronic management, and when to seek assistance. Both patients and their families need to be informed and vigilant. Some key points to convey during patient education include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients and their families should be able to recognize early warning signs of hepatic encephalopathy, such as changes in sleep patterns, the onset of confusion, or a shortened attention span.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Awareness of potential triggers is crucial, including infections, constipation, sedative medications, gastrointestinal bleeding, and dehydration.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients should be advised to steer clear of potential hepatotoxins, such as alcohol and certain herbal medications.</p>
          </list-item>
          <list-item>
            <p>Compliance with prescribed medications is essential. Patients on chronic lactulose therapy should ensure they have at least&#x000a0;2 to&#x000a0;3 bowel movements per day, while those prescribed rifaximin should adhere to their treatment plan. This is key for the effectiveness of these medications.</p>
          </list-item>
          <list-item>
            <p>Immediate medical attention should be sought if symptoms like fever, worsening abdominal distension, increased jaundice, difficulty staying awake, or deteriorating mental status develop</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21070.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Hepatic encephalopathy secondary to acute liver failure involves a presentation&#x000a0;with distinct differences&#x02014;primarily attributable to the development of rapid brain swelling and the relatively rapid deterioration of the condition in acute liver failure. In this section, some of the key aspects are discussed.</p>
        <p>
<bold>Hepatic Encephalopathy in Acute Liver Failure</bold>
</p>
        <p>Acute liver failure is characterized by severe acute liver injury accompanied by impaired synthetic function (INR of &#x02265;1.5) and altered mental status, typically occurring in patients without preexisting liver disease or cirrhosis.<xref ref-type="bibr" rid="article-21070.r58">[58]</xref></p>
        <p><bold>Causes of Acute&#x000a0;Liver Failure:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Acetaminophen (paracetamol) toxicity</p>
          </list-item>
          <list-item>
            <p>Viral hepatitis</p>
          </list-item>
          <list-item>
            <p>Autoimmune hepatitis</p>
          </list-item>
          <list-item>
            <p>Ischemic hepatopathy</p>
          </list-item>
          <list-item>
            <p>Veno-occlusive disease</p>
          </list-item>
          <list-item>
            <p>Acute fatty liver of pregnancy</p>
          </list-item>
          <list-item>
            <p>Toxin exposure, including mushroom poisoning</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
        </list>
        <p>
<bold>Evaluation and Management of Hepatic Encephalopathy Secondary to Acute Liver Failure</bold>
</p>
        <p>The classification of stages of hepatic encephalopathy remains similar for both acute liver failure and cirrhosis. In patients experiencing acute liver failure with hepatic encephalopathy, cerebral edema is relatively uncommon in those with West Haven grade 1 or 2 encephalopathy. However, it is observed in approximately 25% to 35% of patients with grade 3 encephalopathy and about 75% of those with grade 4 encephalopathy.<xref ref-type="bibr" rid="article-21070.r59">[59]</xref><xref ref-type="bibr" rid="article-21070.r60">[60]</xref> The presence of increased intracranial pressure can lead to manifestations such as systemic hypertension, bradycardia, respiratory depression (referred to as Cushing triad), seizures, and abnormal brainstem reflexes.</p>
        <p>The optimal approach to managing increased intracranial pressure in acute liver failure or fulminant hepatic failure remains a topic of uncertainty. Potential treatments that may be considered in this situation include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevating the head end of the bed by 30 degrees</p>
          </list-item>
          <list-item>
            <p>In ventilated patients, the cautious use of short-term sedatives to prevent patient-ventilator dyssynchrony</p>
          </list-item>
          <list-item>
            <p>Administering a bolus of mannitol or hypertonic saline</p>
          </list-item>
        </list>
        <p>In cases of irreversible fulminant hepatic failure, liver transplantation may become necessary as a life-saving intervention. The use of the molecular adsorbent recirculating system (MARS) may be effective in preparing patients with fulminant hepatic failure for liver transplantation. However, it's important to note that MARS therapy can potentially worsen coagulopathy.<xref ref-type="bibr" rid="article-21070.r1">[1]</xref></p>
      </sec>
      <sec id="article-21070.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hepatic encephalopathy carries a poor prognosis, with more than 40% of patients succumbing within 12 months of diagnosis. Given this high mortality rate, it is imperative to establish an interprofessional healthcare team that can closely monitor and manage the patient to enhance their quality of life. Upon diagnosis, it is crucial to refer the patient to a liver transplant surgeon for a thorough assessment of their eligibility for transplantation. Internists, gastroenterologists, hepatologists, neurologists, neurointensivists, and radiologists are key members of the treatment team.</p>
        <p>Pharmacists play a critical role in this process by overseeing the medications prescribed to the patient. Some of the medications can not only exacerbate the condition but may also persist in the body for extended periods since the liver does not efficiently metabolize them. Adjusting medication dosages and avoiding potentially liver-toxic drugs&#x000a0;are essential to management.</p>
        <p>The nursing staff should take the initiative to educate the patient and their family about the disorder, its progression, and its potential complications. It is essential to monitor any changes in the patient's mental status closely. Many patients with hepatic encephalopathy may have limited insight into their disease and may struggle to perform daily living activities. In such cases, a consultation with a social worker, home care nurse, and physical therapist is strongly advised.</p>
        <p>Furthermore, involving a dietitian is crucial to ensure the patient receives an adequate calorie intake. While various treatment modalities can contribute to a better quality of life, the overall prognosis for most patients remains grim. None of the current treatments offer a cure, and liver transplantation is not readily accessible to most patients. Given the significant burden posed by this disease, an interprofessional approach is highly recommended.</p>
      </sec>
      <sec id="article-21070.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21070&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21070">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/hepatic-encephalopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21070">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21070/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21070">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21070.s21">
        <title>References</title>
        <ref id="article-21070.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijdicks</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Hepatic Encephalopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Oct</month>
            <day>27</day>
            <volume>375</volume>
            <issue>17</issue>
            <fpage>1660</fpage>
            <page-range>1660-1670</page-range>
            <pub-id pub-id-type="pmid">27783916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajaj</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy.</article-title>
            <source>Hepatology</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>2014</fpage>
            <page-range>2014-21</page-range>
            <pub-id pub-id-type="pmid">19787808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schomerus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamster</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Blunck</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reinhard</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D&#x000f6;lle</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.</article-title>
            <source>Dig Dis Sci</source>
            <year>1981</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>622</fpage>
            <page-range>622-30</page-range>
            <pub-id pub-id-type="pmid">7249898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>C&#x000f3;rdoba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flavi&#x000e0;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esteban</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guardia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychological abnormalities in cirrhosis include learning impairment.</article-title>
            <source>J Hepatol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-10</page-range>
            <pub-id pub-id-type="pmid">16169117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Minimal hepatic encephalopathy.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>57</volume>
            <fpage>760</fpage>
            <page-range>760-3</page-range>
            <pub-id pub-id-type="pmid">20329443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fichet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mercier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gen&#x000e9;e</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Legras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dequin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Perrotin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy.</article-title>
            <source>J Crit Care</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>364</fpage>
            <page-range>364-70</page-range>
            <pub-id pub-id-type="pmid">19327960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Mart&#x000ed;nez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sim&#x000f3;n-Talero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>C&#x000f3;rdoba</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prognostic assessment in patients with hepatic encephalopathy.</article-title>
            <source>Dis Markers</source>
            <year>2011</year>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-9</page-range>
            <pub-id pub-id-type="pmid">22045403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saad</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy.</article-title>
            <source>Semin Intervent Radiol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>262</fpage>
            <page-range>262-5</page-range>
            <pub-id pub-id-type="pmid">25177088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000f6;ssle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ochs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sellinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000f6;ldge</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perarnau</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gabelmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauenstein</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding.</article-title>
            <source>N Engl J Med</source>
            <year>1994</year>
            <month>Jan</month>
            <day>20</day>
            <volume>330</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-71</page-range>
            <pub-id pub-id-type="pmid">8264738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riggio</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Angeloni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salvatori</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Farcomeni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attili</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>2738</fpage>
            <page-range>2738-46</page-range>
            <pub-id pub-id-type="pmid">18775022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajesh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Philips</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ahamed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abduljaleel</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects.</article-title>
            <source>Can J Gastroenterol Hepatol</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>8795115</fpage>
            <pub-id pub-id-type="pmid">34422711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tapper</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Sengupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mellinger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ratz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.</article-title>
            <source>Hepatology</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>1498</fpage>
            <page-range>1498-1507</page-range>
            <pub-id pub-id-type="pmid">29091289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orman</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghabril</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nephew</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Patidar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>Jun</month>
            <day>05</day>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>e196412</fpage>
            <pub-id pub-id-type="pmid">31251379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potnis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>VanMeter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stange</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States.</article-title>
            <source>Int J Hepatol</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>8542179</fpage>
            <pub-id pub-id-type="pmid">34211786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterworth</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Gigu&#x000e8;re</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lavoie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Layrargues</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Ammonia: key factor in the pathogenesis of hepatic encephalopathy.</article-title>
            <source>Neurochem Pathol</source>
            <year>1987</year>
            <season>Feb-Apr</season>
            <volume>6</volume>
            <issue>1-2</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">3306479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterworth</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Spahr</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Layrargues</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy.</article-title>
            <source>Metab Brain Dis</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-67</page-range>
            <pub-id pub-id-type="pmid">8847990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterworth</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities.</article-title>
            <source>J Steroid Biochem Mol Biol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>160</volume>
            <fpage>94</fpage>
            <page-range>94-7</page-range>
            <pub-id pub-id-type="pmid">26589093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterworth</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure.</article-title>
            <source>J Clin Exp Hepatol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>Suppl 1</issue>
            <fpage>S96</fpage>
            <page-range>S96-S103</page-range>
            <pub-id pub-id-type="pmid">26041966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterworth</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy in alcoholic cirrhosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2014</year>
            <volume>125</volume>
            <fpage>589</fpage>
            <page-range>589-602</page-range>
            <pub-id pub-id-type="pmid">25307598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nardelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lattanzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Torrisi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Farcomeni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gioia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riggio</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>934</fpage>
            <page-range>934-936</page-range>
            <pub-id pub-id-type="pmid">27816756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijarnpreecha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Werlang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panjawatanan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kroner</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lukens</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Pungpapong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis.</article-title>
            <source>Ann Hepatol</source>
            <year>2020</year>
            <season>May-Jun</season>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-250</page-range>
            <pub-id pub-id-type="pmid">31422030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khungar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Poordad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy.</article-title>
            <source>Clin Liver Dis</source>
            <year>2012</year>
            <month>May</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-20</page-range>
            <pub-id pub-id-type="pmid">22541700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cadranel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lebiez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Martino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>El Koury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tourbah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pidoux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Valla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Opolon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?</article-title>
            <source>Am J Gastroenterol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>515</fpage>
            <page-range>515-8</page-range>
            <pub-id pub-id-type="pmid">11232699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>STAHL</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance.</article-title>
            <source>Ann Intern Med</source>
            <year>1963</year>
            <month>Jan</month>
            <volume>58</volume>
            <fpage>1</fpage>
            <page-range>1-24</page-range>
            <pub-id pub-id-type="pmid">13978712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montoliu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cauli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Urios</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>ElMlili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Giner-Duran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Lopez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Del Olmo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wassel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Felipo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>9</issue>
            <fpage>1629</fpage>
            <page-range>1629-37</page-range>
            <pub-id pub-id-type="pmid">21483460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rikkers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jenko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rudman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freides</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.</article-title>
            <source>Gastroenterology</source>
            <year>1978</year>
            <month>Sep</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>462</fpage>
            <page-range>462-9</page-range>
            <pub-id pub-id-type="pmid">680502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conn</surname>
                <given-names>HO</given-names>
              </name>
            </person-group>
            <article-title>Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.</article-title>
            <source>Am J Dig Dis</source>
            <year>1977</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>541</fpage>
            <page-range>541-50</page-range>
            <pub-id pub-id-type="pmid">868833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Piccolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Iemmolo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caregaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerunda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gatta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.</article-title>
            <source>Hepatology</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>1662</fpage>
            <page-range>1662-7</page-range>
            <pub-id pub-id-type="pmid">10347105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Piccolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iemmolo</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gerunda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caregaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gatta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Visual attention in cirrhotic patients: a study on covert visual attention orienting.</article-title>
            <source>Hepatology</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>1517</fpage>
            <page-range>1517-23</page-range>
            <pub-id pub-id-type="pmid">9620321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weissenborn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ckert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy.</article-title>
            <source>J Hepatol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>646</fpage>
            <page-range>646-53</page-range>
            <pub-id pub-id-type="pmid">9566834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krieger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theilmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lichtnecker</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Manganese and chronic hepatic encephalopathy.</article-title>
            <source>Lancet</source>
            <year>1995</year>
            <month>Jul</month>
            <day>29</day>
            <volume>346</volume>
            <issue>8970</issue>
            <fpage>270</fpage>
            <page-range>270-4</page-range>
            <pub-id pub-id-type="pmid">7630246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thuluvath</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Edwin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>deVilliers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy.</article-title>
            <source>Hepatology</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>440</fpage>
            <page-range>440-2</page-range>
            <pub-id pub-id-type="pmid">7843718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krieger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jauss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Theilmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Geissler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis.</article-title>
            <source>Gastroenterology</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <page-range>147-55</page-range>
            <pub-id pub-id-type="pmid">8698193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferenci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herneth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steindl</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Newer approaches to therapy of hepatic encephalopathy.</article-title>
            <source>Semin Liver Dis</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-38</page-range>
            <pub-id pub-id-type="pmid">8989818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conn</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Leevy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vlahcevic</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Maddrey</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Seeff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.</article-title>
            <source>Gastroenterology</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4 Pt 1</issue>
            <fpage>573</fpage>
            <page-range>573-83</page-range>
            <pub-id pub-id-type="pmid">14049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Disaccharides in the treatment of hepatic encephalopathy.</article-title>
            <source>Metab Brain Dis</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-20</page-range>
            <pub-id pub-id-type="pmid">23456517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valpiani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossellini</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ferrieri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.</article-title>
            <source>Curr Med Res Opin</source>
            <year>1997</year>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>593</fpage>
            <page-range>593-601</page-range>
            <pub-id pub-id-type="pmid">9327194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tramote</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Caly</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Honain</surname>
                <given-names>NZ</given-names>
              </name>
              <name>
                <surname>Maffei</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>de S&#x000e1;</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.</article-title>
            <source>Hepatogastroenterology</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-5</page-range>
            <pub-id pub-id-type="pmid">1483668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <collab>Korean Association for the Study of the Liver (KASL)</collab>
            <article-title>KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.</article-title>
            <source>Clin Mol Hepatol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-127</page-range>
            <pub-id pub-id-type="pmid">31918536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DiMartini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>1144</fpage>
            <page-range>1144-65</page-range>
            <pub-id pub-id-type="pmid">24716201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopp</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dirks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petrusch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goldbecker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tryc</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Barg-Hock</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Strassburg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klempnauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weissenborn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pflugrad</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hepatic Encephalopathy Is Reversible in the Long Term After Liver Transplantation.</article-title>
            <source>Liver Transpl</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1661</fpage>
            <page-range>1661-1672</page-range>
            <pub-id pub-id-type="pmid">31437344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naylor</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Detsky</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis.</article-title>
            <source>Gastroenterology</source>
            <year>1989</year>
            <month>Oct</month>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>1033</fpage>
            <page-range>1033-42</page-range>
            <pub-id pub-id-type="pmid">2506095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis.</article-title>
            <source>World J Clin Cases</source>
            <year>2022</year>
            <month>Oct</month>
            <day>26</day>
            <volume>10</volume>
            <issue>30</issue>
            <fpage>10984</fpage>
            <page-range>10984-10996</page-range>
            <pub-id pub-id-type="pmid">36338230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gluud</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Dam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Les</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marchesini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aagaard</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Vilstrup</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Branched-chain amino acids for people with hepatic encephalopathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>May</month>
            <day>18</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD001939</fpage>
            <pub-id pub-id-type="pmid">28518283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahimi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Singal</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cuthbert</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rockey</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>174</volume>
            <issue>11</issue>
            <fpage>1727</fpage>
            <page-range>1727-33</page-range>
            <pub-id pub-id-type="pmid">25243839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoilat</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Ayas</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hoilat</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Abu-Zaid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Durer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Durer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adhami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis.</article-title>
            <source>BMJ Open Gastroenterol</source>
            <year>2021</year>
            <month>May</month>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34006606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sushma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dasarathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhist</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial.</article-title>
            <source>Hepatology</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>138</fpage>
            <page-range>138-44</page-range>
            <pub-id pub-id-type="pmid">1618465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Riordan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Probiotics for people with hepatic encephalopathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Feb</month>
            <day>23</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD008716</fpage>
            <pub-id pub-id-type="pmid">28230908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goh</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jul</month>
            <day>26</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD002798</fpage>
            <pub-id pub-id-type="pmid">28745801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loomba</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pawar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dhar</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Setia</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Serum zinc levels in hepatic encephalopathy.</article-title>
            <source>Indian J Gastroenterol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>51</fpage>
            <page-range>51-3</page-range>
            <pub-id pub-id-type="pmid">7797277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilstrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cordoba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferenci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Weissenborn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>715</fpage>
            <page-range>715-35</page-range>
            <pub-id pub-id-type="pmid">25042402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patidar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>2048</fpage>
            <page-range>2048-61</page-range>
            <pub-id pub-id-type="pmid">26164219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of hepatic encephalopathy for survival of patients with liver failure: A systematic review and meta-analysis.</article-title>
            <source>Ann Hepatol</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>607</fpage>
            <page-range>607-612</page-range>
            <pub-id pub-id-type="pmid">31085039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Worland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terbah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.</article-title>
            <source>World J Gastroenterol</source>
            <year>2020</year>
            <month>May</month>
            <day>14</day>
            <volume>26</volume>
            <issue>18</issue>
            <fpage>2221</fpage>
            <page-range>2221-2231</page-range>
            <pub-id pub-id-type="pmid">32476788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saleh</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Solano</surname>
                <given-names>QP</given-names>
              </name>
              <name>
                <surname>Louissaint</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jepsen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tapper</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis.</article-title>
            <source>United European Gastroenterol J</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>672</fpage>
            <page-range>672-680</page-range>
            <pub-id pub-id-type="pmid">34102040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endale Simegn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yaregal Melesse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Belay Bizuneh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mekonnen Alemu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Perioperative management of patients with liver disease for non-hepatic surgery: A systematic review.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>75</volume>
            <fpage>103397</fpage>
            <pub-id pub-id-type="pmid">35242334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Makker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Balar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Perioperative Care of Patients With Liver Cirrhosis: A Review.</article-title>
            <source>Health Serv Insights</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>1178632917691270</fpage>
            <pub-id pub-id-type="pmid">28469455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Stravitz</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.</article-title>
            <source>Hepatology</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>965</fpage>
            <page-range>965-7</page-range>
            <pub-id pub-id-type="pmid">22213561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Acute liver failure.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Dec</month>
            <day>16</day>
            <volume>329</volume>
            <issue>25</issue>
            <fpage>1862</fpage>
            <page-range>1862-72</page-range>
            <pub-id pub-id-type="pmid">8305063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21070.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Difficult management problems in fulminant hepatic failure.</article-title>
            <source>Semin Liver Dis</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>395</fpage>
            <page-range>395-413</page-range>
            <pub-id pub-id-type="pmid">8303321</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
